Physician

Patrick M Travis, M.D.

According to 2025 Medicare claims, Patrick Travis, M.D. (NPI: 1104897099) practices medical oncology in the Fayetteville-Springdale-Rogers, AR market, with the plurality of this provider's patient population coming from Benton, AR. This provider's primary affiliated billing organization is HIGHLANDS ONCOLOGY GROUP PA (NPI: 1346211323; TIN: 710788742) and primary practice location at 72758-8602. Travis is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616), participating under the MSSP model.

Travis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,428 traditional Medicare patients, billed 300,404 HCPCS/CPT codes, and received $5,437,931 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 5,065 prescription claims across 598 beneficiaries totaling $9,251,004 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 158 claims. Open Payments data shows 75 records totaling $229,256. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,661,289 to $9,251,004. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $31,575 to $9,919.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,262	332,001	$4,309,427
2016	1,244	316,801	$5,009,725
2017	1,439	424,385	$6,551,436
2018	1,377	415,717	$6,053,736
2019	1,572	515,103	$6,469,998
2020	1,293	316,524	$5,001,271
2021	1,444	386,423	$6,151,819
2022	1,501	417,685	$6,920,216
2023	1,288	348,013	$5,208,264
2024	1,428	300,404	$5,437,931

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	480	5,333	$2,661,289
2016	491	5,297	$3,518,055
2017	487	4,823	$3,543,097
2018	502	4,763	$4,567,261
2019	643	4,621	$4,661,275
2020	630	4,222	$3,987,685
2021	524	4,435	$5,251,383
2022	537	4,600	$6,156,534
2023	570	4,607	$7,030,864
2024	598	5,065	$9,251,004

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	277	$29,741
2016	26	227	$16,538
2017	17	223	$10,568
2018	12	141	$7,509
2019	N/R	166	$10,263
2020	N/R	296	$21,156
2021	15	206	$14,074
2022	15	206	$12,708
2023	15	246	$24,367
2024	N/R	158	$6,575

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	842	3,347	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	875	3,574	$8
83735	Magnesium level	824	3,341	$7
83615	Lactate dehydrogenase (enzyme) level	819	3,312	$6
84100	Phosphate level	820	3,317	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	88	2,443	$1,972,606
Revlimid	Lenalidomide	90	2,464	$1,458,885
Calquence	Acalabrutinib Maleate	72	2,160	$1,087,566
Jakafi	Ruxolitinib Phosphate	50	1,530	$818,637
Cabometyx	Cabozantinib S-Malate	18	540	$443,691

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	67	$5,050
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	45	$738
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$373
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$263
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$4,501	Rigel Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	19	$224,755	Takeda Pharmaceuticals U.S.A., Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Patrick M. Travis, M.D.?

Tedicare shows public-source Medicare data for Patrick M. Travis, M.D. (NPI 1104897099), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Patrick M. Travis, M.D. have ACO affiliation data?

Patrick M. Travis, M.D. is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616).

What billing organization is linked to Patrick M. Travis, M.D.?

Patrick M. Travis, M.D. is linked to HIGHLANDS ONCOLOGY GROUP PA (billing NPI 1346211323) in the available physician profile data.

Does Patrick M. Travis, M.D. have Open Payments data?

Patrick M. Travis, M.D. has 75 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.